Background: BPR0L075 [6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole] is a
INTRODUCTON
Microtubules are protein filaments of cytoskeleton composed of α-tubulin and β-tubulin molecules (Sawada & Cabral, 1989; Wade & Hyman, 1997) . In cells, microtubule filaments rapidly alternate between phases of growth and shrinkage (dynamic instability) during cell cycle. Since microtubules play crucial roles in the regulation of the mitotic apparatus, disruption of microtubules can induce cell cycle arrest in M phase, the formation of abnormal mitotic spindles, and final triggering of signals for apoptosis. The discovery that the cytotoxic activity of various compounds is through interference with the mitotic spindle apparatus has attracted much attention within the past two decades, and microtubules have become an attractive pharmacologic target for anticancer drug discovery (Kiselyov et al., 2007; Shi et al., 1998) . Anti-mitotic compounds such as vincristine, vinblastine (microtubule-destabilizing Vinca alkaloid) and paclitaxel (microtubule-stabilizing taxane) have been developed to target cancers recently (Arrieta et al., 2006; Raitanen et al., 2002; Tanaka et al., 2004) . Although the taxanes and Vinca alkaloids are effective for the management of different malignancies, their potential is limited by the development of multidrug resistance (MDR) (Cornelissen et al., 1994; Dumontet & Sikic, 1999) . MDR is multi-factorial, with one pathway leading to resistance mediated by over-expression of transmembrane efflux pumps, namely, the M r 170,000 P-glycoprotein (P-gp170/MDR) and the multidrug resistance protein (MRP) (Deng et al., 2002) . Therefore, there has been great interest in identifying novel microtubule inhibitors that can overcome various modes of resistance and have improved pharmacology profiles.
BPR0L075 [6-methoxy-3-(3',4',5 '-trimethoxy-benzoyl)-1H-indole] is a novel synthetic compound discovered through research to identify new microtubule inhibitors. It is a heterocyclic Combretastatin A-4 (CA-4) analog, which is derived from the South African tree Combretum caffrum, and inhibits tubulin polymerization by binding to tubulin at the colchicine-binding site (Kuo et al., 2004a; Liou et al., 2004) . Unlike traditional microtubule inhibitors such as vincristine and paclitaxel; BPR0L075 (L075) is effective in suppressing cell growth of both MDR-positive and -negative tumor cell lines (Kuo et al., 2004a) . L075 also induces phosphorylation of Bcl-2 and activation of caspase-3 (Kuo et al., 2004a) . In-vivo, L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells in nude mice (Kuo et al., 2004a) . Thus, L075 is a promising anticancer compound with anti-mitotic activity that can be applied to the management of various malignancies, particularly for patients with MDR-related drug resistance. Phase I clinical trial of L075 is planned and will be initiated in the near future.
Besides overexpression of MDR, inaccurate expression of survivin also induces drug resistance in various cancers (Zaffaroni & Daidone, 2002) . Survivin belongs to the family of inhibitors of apoptosis (IAPs). Unlike other IAPs such as XIAP and IAP-1, survivin is not expressed in differentiated normal tissue (Reed, 2001; Satoh et al., 2001; Tanaka et al., 2003) . In clinical situations, survivin seems to play an important role in the transition of adenoma with low dysplasia to high dysplasia during human colorectal tumorigenesis (Kawasaki et al., 2001 ). The median survival period for patients with high survivin expression was less than that for patients with low levels of expression after chemotherapy treatment, suggesting that survivin expression correlates with a poor prognosis (Kato et al., 2001) . Expression of survivin has been related to the causation of cancer-drug resistance in various studies (Pennati et al., 2007) . Growing evidence indicates that transient upregulation of survivin by VEGF and bFGF in normal endothelial cells of blood vessel is partially responsible for tumor angiogenesis and tumor resistance against chemotherapeutic drugs (O' Connor et al., 2000; Tran et al., 2002) . At the molecular level, survivin is a bifunctional protein that acts as a suppressor of apoptosis and plays a central role in cell division. It has been suggested that survivin, possibly the mitochondrial fraction instead of the cytosol fraction, inhibits apoptosis through interference with caspases (Dohi et al., 2004; Shin et al., 2001; Tamm et al., 1998) . Survivin also promotes cell survival through interference with cell cycle-related kinases and microtubule networks. Complex formation between survivin, INCENP and Aurora-B kinase was found on the centromere, and over-expression of survivin has been shown to elevate Aurora-B activity in-vitro (Geddis & Kaushansky, 2004) . Overexpression of survivin reduced centrosomal microtubule nucleation and suppressed both microtubule dynamics instability in mitotic spindles and bidirectional growth of microtubules in midbodies during cytokinesis (Rosa et al., 2006) . It has been shown that intracellular loading of a polyclonal antibody to survivin induced microtubule defects and resulted in formation of multipolar mitotic spindles (Fortugno et al., 2002) . In addition, gene knockout studies and tubulin staining revealed that the absence of normal mitotic spindle structures and intercellular midbodies were related to the absence of survivin protein Li et al., 1998; Rosa et al., 2006) .
Since survivin is associated with microtubules, apoptosis, and drug resistance, it is possible that this molecule can contribute to the cell response to our microtubuledestabilizing compound, BPR0L075. In this study, we describe the role of survivin in interfering sensitivity to BPR0L075 in human oral carcinoma cells.
MATERIALS AND METHODS

Drug
The compound BPR0L075 was synthesized at the Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan, ROC.
BPR0L075 was obtained in 72% yield from 6-methoxyindole and 3,4,5-trimethoxybenzoyl chloride. The detailed synthetic method was previously published. (Liou et al., 2004) 
Cell lines, antibodies and reagents
The human oral carcinoma cells (KB) were purchased from the American Type Culture 
RT-PCR
SDS-PAGE and Western Blot Analysis
Cells were lysed with ice-cold lysis buffer ( MTT cell viability assay 3 x 10 3 cells in 100 μL of drug-free culturing medium were seeded on 96-well plates for 24 hours before treatments. Cells were then treated with various concentration of BPR0L075 for 72 hours. 25 μL of MTT (5 mg/mL) was added into each sample and incubated for 4 hours, under 5% CO 2 and 37 o C. 100 μL of lysis buffer (20% SDS, 50% DMF) was subsequently added into each sample and further reacted for 16 hours. IC 50 value resulting from 50% inhibition of cell growth was calculated graphically as a comparison with control growth.
Immunofluorescent microscopy
Cells were cultured in 8-well chamber slides, fixed with 4% paraformaldehyde, and permeabilized with TPBS. They were incubated with primary antibody for 60 min at room temperature followed by FITC-conjugated secondary antibody. Slides were examined by microscopy using an Olympus BX50 microscope (Olympus optical co., LTD, Tokyo, Japan 
Visualization of apoptosis by the TUNEL assay
Cells were seeded and cultured in 8-well chamber-slides, and treated with various treatments. The cells were washed with PBS, fixed with 4% paraformaldehyde for 30 min on ice, and permeabilized with TPBS at room temperature. Apoptotic cells were stained by the TUNEL agent using an In-Situ Apoptosis Detection TMR Kit (Roche Diagnostic, Mannheim, Germany). Cells were counter-stained with DAPI to detect nucleus, and examined by fluorescence microscopy.
RESULTS
BPR0L075 induces up-regulation of survivin protein expression
Human p53-wildtype KB and p53-mutated HONE-1 cancer cell lines were used in this study. Cells were treated with 8 nM (IC 50 value) of L075 for 24 h. Cell lysate were extracted and expressions of various intracellular proteins were analyzed by western blotting. A time-dependent phosphorylation of Bcl2 in both cell lines was shown and this result is consistent with our previously published data ( Figure 1A ) (Kuo et al., 2004a) .
Expression of p53 was also increased in L075-treated KB cells in a time-dependent manner where an increase of p53 in L075-treated HONE-1 cells was observed at 24 h post-treatment ( Figure 1A ). Both un-treated cell lines expressed survivin endogenously ( Figure 1A) . Surprisingly, treatment of L075 induced over-expression of survivin in a time-dependent manner ( Figure 1A ). KB cells were chosen for further in-vitro investigation; consider that the same cell line was chosen in our previously published report (Kuo et al., 2004a) .
BPR0L075 induces survivin gene transcription
To determine whether L075-induced over-expression of survivin in KB cells was caused by changes in the rate of survivin gene transcription, RT-PCR was performed. As was observed for the protein, level of survivin mRNA transcripts was increased in KB cells after 24 h of L075 incubation ( Figure 1B ). Western blot analysis revealed that coincubation with a gene transcription inhibitor, actinomycin-D, was able to reduce the amount of survivin protein in L075-treated cells ( Figure 1C ). Heat shock protein 90 (Hsp90) has been suggested to stabilize survivin in-vitro (Fortugno et al., 2003b; Suriawinata, 2004) . Here, co-incubation of a Hsp90 inhibitor, geldanamycin, was unable to reduce the amount of intracellular survivin protein in L075-treated KB cells ( Figure   1C ). However, changes in cell morphology were shown by phase-contrast microscopy ( Figure 1D ).
Down-regulation of survivin enhances sensitivity to BPR0L075 in KB cells
To address whether survivin plays a role in sensitivity to L075 in KB cells, siRNA was applied to down-regulate survivin. Cells were transfected with validated-siRNA oligomers, siR-C (scramble control) or siR-S (survivin specific) by liposomal reagent.
Successful down-regulation of survivin by siR-S after 48 h of transfection was shown by immunofluorescence microscopy ( Figure 2A ). Down-regulation of survivin mRNA transcripts by siRNA after 36 h of transfection was further confirmed by RT-PCR (Fig.   2B ).
Changes in cell morphology were observed in survivin down-regulated KB cells and revealed by phase-contrast microscopy. Survivin-targeted cells became round and slightly enlarged in size ( Figure 3A ). Although inhibition of survivin by siR-S induced morphological changes in KB cells under L075-free conditions ( Figure 3A) , the same treatment did not reduce cell viability ( Figure 3B ). Interestingly, down-regulation of survivin by siR-S enhanced sensitivity to L075 in KB cells in-vitro. Treatment with siR-S reduced cell viability of KB by 21-31% among various concentrations of L075 compared to L075 monotherapy ( Figure 3B ).
Inhibition of survivin enhances sensitivity to BPR0L075 via a caspase-independent mechanism
To determine whether down-regulation of survivin enhances sensitivity to L075 in KB cells via a caspase-dependent mechanism, a real-time caspase-3/-7 activity imaging was performed. KB cells were seeded on 8-well chamber slides. Cells were transfected with siR-C and siR-S for 24 h and co-incubated with L075 for various times. Real-time caspase-3/-7 activity assay was used and cells were viewed under microscope. Incubation of L075 induced caspase-3/-7 activity as expected ( Figure 4A) . Surprisingly, inhibition of survivin by siR-S did not induce caspase-3/-7 activity in KB cells under L075-free condition ( Figure 4A and 4B). In addition, co-treatment of siR-S and L075 did not enhance caspase-3/-7 activity, compared to the L075 monotherapy at various time points ( Figure 4B ).
Nucleus degradation was observed with KB cells treated with 16 nM (twice of IC 50
value) of L075 after 72 h (data not shown) (Kuo et al., 2004a) . Here, combination of siR-S and 4 nM of L075 induced massive degradation of nucleus in KB cells. In contrast, cells treated with 4 nM of L075 did not induce similar molecular phenotype ( Figure 4A ).
DNA fragmentation was further analyzed by TUNEL assay and immunofluorescence microscopy. In TUNEL analysis, nucleus of cells co-treated siR-S and L075 were stained red, suggesting that DNA fragmentation occurred in the nucleus ( Figure 4C ). In contrast, nucleus of KB cells treated with siR-C, siR-S or L075 were not stained red by the TUNEL reagent ( Figure 4C ).
Down-regulation of survivin induces translocation of apoptosis-inducing factor in KB cells
Translocation of apoptosis-inducing factor (AIF) occurs during caspase-independent apoptosis. The possibility that siRNA-mediated down-regulation of survivin leads to the translocation of AIF was explored. KB cells were treated with siR-C, siR-S, or drug L075 alone, and AIF expression was examined by immunofluorescence microscopy using an anti-AIF antibody. The cytoplasm of cells treated with siR-C for 48 h was stained green with a ring-like pattern around the nucleus by the anti-AIF antibody, as was the cytoplasm of cells treated with L075 ( Figure 4D ). In marked contrast, it was the nucleus that was stained green by the anti-AIF antibody in cells treated with the siR-S against survivin, suggesting that AIF translocated from cytoplasm to the nucleus when survivin was targeted with siRNA ( Figure 4D ). Cells treated with a combination of siR-S and L075 induced similar phenotype to siR-S mono-treatment (data not shown).
Survivin interferes with the microtubule dynamics
To determine whether sensitivity to L075 in KB cells is also related to survivin-interfered microtubule dynamics, insoluble fraction of cell lysate were analyzed by western blotting. Application of siR-S reduced the amount of insoluble α-tubulin in KB cells after 72 h of transfection ( Figure 5A ). In contrast, down-regulation of survivin did not induce any change in general expression of α-tubulin ( Figure 5A ). Immuno-staining of α-tubulin in KB cells was performed to determine the integrity of microtubule networks. Normal KB cells showed intact microtubule networks ( Figure 5B ). In contrast, down-regulation of survivin by siR-S induced disorganization of the microtubule networks ( Figure 5B ).
Furthermore, combination of siR-S and 4 nM of L075 induced synergistic microtubule depolarization and changes in cell morphology ( Figure 5B ).
A KB-derived L075-resistant cancer cell line, KB-L30, was recently generated in our laboratory. This drug-resistant cell line was shown to withstand 30 nM of L075 under culturing condition (data not shown). In comparison to KB cells, western blot analysis revealed that expression of survivin was increased by approximately 2-fold in L075-resistant KB-L30 ( Figure 5C ). In correlation, amount of insoluble α-tubulin and β-tubulin were also increased in the cells ( Figure 5D ). siRNA was used to down-regulate survivin in KB-L30 cells. Levels of survivin mRNA transcript were successfully down-regulated by siR-S after 36 h of transfection ( Figure 5E ). Application of siR-S reduced the amount of insoluble α-tubulin in KB-L30 cells after 72 h of transfection ( Figure 5F ).
Down-regulation of survivin enhances sensitivity to BPR0L075 in KB-L30 cells
Since 
DISCUSSION
Over-expression of survivin has been shown to induce drug resistance in cancers. In an example, over-expression of wildtype survivin by gene transfection mediated resistance to anti-androgen therapy in prostate cancer cells (Zhang et al., 2005a) . In addition, adenovirus-mediated inhibition of survivin expression sensitized human prostate cancer cells to paclitaxel in-vitro and in-vivo (Zhang et al., 2005b) . Given such evidences implicating survivin's role in drug resistance, survivin may also play a role in the sensitivity and resistancy to our newly developed tubulin de-polymerizing compound BPR0L075 in cancers.
Here, we report that BPR0L075 induced co-expression of survivin and p53 in both p53-wildtype KB and p53-mutated HONE-1 cancer cells in a time-dependent manner. The amount of survivin within cells seems to be controlled by two different mechanisms, namely gene transcription and protein stabilization (Fortugno et al., 2003a; Li & Altieri, 1999; Zhu et al., 2004) . Mutations in the CDE/CHR repressor element within survivin promoter region were shown to increase survivin gene transcription (Xu et al., 2004 ). At post-translational level, molecular chaperones such as heat shock protein 90 (Hsp90) were shown to stabilize survivin protein in-vitro (Fortugno et al., 2003b; Suriawinata, 2004) . In our study, the Hsp90 inhibitor, geldanamycin, did not alter the over-expression of survivin protein in response to BPR0L075 while the gene transcription inhibitor, actinomycin-D, completely abrogated BPR0L075-induced changes in survivin protein expression. Together with the result from RT-PCR, decreases in survivin protein in response to BPR0L075 in the presence of actinomycin-D may reflect increased gene transcription. Expression of survivin is thought to be negatively regulated by p53 (Ikeda et al., 2007; Mirza et al., 2002; Raj et al., 2008; Yonesaka et al., 2006; Zhou et al., 2002; Zhu et al., 2006) . However, whether p53 plays a definite role in survivin regulation under various chemo-stresses remains agurable. In fact, a new class of anticancer drug, Geranylgeranyltransferase I inhibitors (GGTIs), induce cancer cells cell death by downregulation of survivin through a p53-independent pathway (Dan et al., 2004) .
Furthermore, co-expression of survivin and p53 in response to a flavonoid, Quercetin, has been demonstrated previously (Kuo et al., 2004b) . Interestingly, co-incubation of a p53-inhibitor, pifithrin-α, was unable to increase the level of survivin expression in BPR0L075-treated KB cells (supplemental data). The present study suggests that BPR0L075 induces overexpression of survivin through a p53-independent pathway.
Indeed, further investigation should be undertaken to determine the pathway of BPR0L075-induced survivin expression.
As mentioned previously, survivin plays important roles in the dynamic polymerization of microtubule and induction of drug resistance. Here, survivin clearly plays a role in the sensitivity to BPR0L075 in human oral carcinoma cells. Survivin also plays a role in the polymerization of microtubule in our tested cell lines. It has been reported that VEGFinduced expression of survivin preserved the microtubule integrity of both CDDP and paclitaxel-treated HUVEC cells. Stabilization of microtubule networks subsequently induced drug-resistance in cells (Tran et al., 2002) . Furthermore, a role for altered microtubule polymer levels in vincristine resistance of acute lymphoblastic leukemia has been demonstrated in-vivo (Ong et al., 2008) . In Ong et al's study, a vincristine-resistant xenograft with high levels of polymerized tubulin was also relatively sensitive to the microtubule-polymerizing drug paclitaxel (Ong et al., 2008) . Interestingly, the BPR0L075-resistant KB-L30 with high levels of polymerized tubulin was relatively sensitive to paclitaxel (data not shown). In addition, KB-L30 cells were relatively resistant to the microtubule-depolymerizing agent BPR0L075, suggesting a positive correlations between the amounts of intracellular survivin, tubulin polymers and levels of drug sensitivity in KB and KB-L30 cells. In our study, survivin stabilizes tubulin polymers in both KB and KB-L30 cells. In contrast, anti-mitotic compound BPR0L075
induces de-polymerization of the microtubule networks. Taken together, over-expression of survivin in response to the BPR0L075 reflects one of the possible cell survival mechanisms by stabilizing microtubule.
In addition to dynamic formation of the microtubule networks, survivin is also involved in the process of both caspase-dependent and -independent apoptosis Shankar et al., 2001) . It has been demonstrated that survivin enhances radiation resistance in primary human glioblastoma cells via a caspase-independent mechanism (Chakravarti et al., 2004) . Our previous study revealed that BPR0L075 induced activation of caspase-3 and DNA fragmentation in KB cells (Kuo et al., 2004a) . Our current study shows that down-regulation of survivin did not induce caspase-3 activity in the same cell line.
However, increased DNA fragmentation was observed in the combination treatments when compared to BPR0L075 monotherapy. During one form of caspase-independent apoptosis, apoptosis-inducing factor (AIF) translocates from the mitochondria to the nucleus (Bajt et al., 2006; Hisatomi et al., 2001; Ye et al., 2002) . AIF is a flavoprotein that is normally confined to the mitochondrial intermembrane space, but induces chromatin condensation and fragmentation of DNA into high molecular weight forms of >50 kb when it translocates to nuclei (Lu et al., 2003; Wang et al., 2002) . Structure-based mutagenesis of AIF revealed that replacing positively charged residues at the protein surface with alanines caused AIF to be defective in DNA-binding . It has been suggested that survivin interferes with the translocation of AIF. In fact, translocation of AIF from the mitochondria to the nucleus was shown in YUSAC2 melanoma cells treated with a cell-permeable dominant-negative survivin protein (Yan et al., 2006) . Translocation of AIF from the cytoplasm to the nucleus following the downregulation of survivin indicates that survivin inhibits caspase-independent apoptosis in KB cells. Thus, both caspase-dependent and caspase-independent DNA fragmentation could be initiated during survivin-targeted BPR0L075 combination therapy.
Drug resistance is a common problem in the management of neoplastic diseases. The effectiveness of a single anti-cancer agent is limited by the fact that "anti-drug" mechanisms can be introduced by cancer cells during cell evolution or re-arrangement of tumor micro-environment. In clinical situations, rather than treating patients with a single anti-cancer agent, combination therapies are preferred. BPR0L075 is a tubulin-targeting compound capable of inducing cytotoxic effect among various MDR-positive/-negative cancers both in-vitro and in-vivo. Here, we propose a novel survivin-involved microtubule-dependent and caspase-independent mechanism which interferes with the BPR0L075-drug sensitivity in human oral carcinoma cells. Since survivin plays an important role in BPR0L075 sensitivity, the use of survivin-targeted agents such as oxaliplatin and SPC3042 (Santaris Pharma) in BPR0L075-combinational therapy maybe of clinical benefit (Fujie et al., 2005; Hansen et al., 2008) . Also, unlike other potential therapeutic targets, survivin is expressed in few adult tissues. Thus, survivin-specific BPR0L075 combination therapy is likely to produce few adverse effects. RT-PCR was performed and PCR products were resolved by DNA electrophoresis. 
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